BETTER BIOMARKERS FOR PREDICTING THE INCIDENCE OF HAVING ATHEROSCLEROSIS AND HEART ATTACKS
With
Associate Professor Christina Bursill
Co-Director, Vascular Research Centre,
South Australian Health and Medical Research Institute (SAHMRI) &
Department of Health and Medical Science,
The University of Adelaide, Australia
RESEARCHER PROFILE
Filmed in Adelaide, Australia | April 2025
Associate Professor Christina Bursill started as Co-director of the Vascular Research Centre in January 2017 at the South Australian Health and Medical Research Institute (SAHMRI) and at The University of Adelaide, Department of Health and Medical Science. She currently holds the Lin Huddleston National Heart Foundation fellowship and is a Chief Investigator on the ARC Centre of Excellence for Nanoscale Biophotonics (CNBP).
Assoc Prof Bursill is a vascular biologist with interests and expertise in vascular inflammation, atherosclerosis and angiogenesis. She completed her PhD at The University of Adelaide in lipid metabolism then headed to Oxford University for five years to undergo a postdoctoral post in the Departments of Cardiovascular Medicine and Pathology. Her postdoctoral time triggered her interest in the mechanisms that cause atherosclerosis and in particular the role of small inflammatory proteins called chemokines.
Assoc Prof Bursill returned to Australia in 2007 at the Heart Research Institute (HRI) in Sydney where she led the Immunobiology Group. In 2008, she was awarded a National Heart Foundation Career Development Fellowship. At the HRI A/Prof Bursill developed an interest in high-density lipoproteins (HDL) and through NHMRC and National Heart Foundation funding, investigated novel mechanisms of their action in models of stent biocompatibility, diabetes and wound healing. She also has an interest in using viral gene transfer techniques to over-express proteins that attenuate chemokine activity to suppress atherosclerosis and inflammatory-driven diseases. A/Prof Bursill currently holds NHMRC Ideas, Heart Foundation Vanguard and Diabetes Australia Millenium grant funding.
Recently, Christina has been focusing on finding ways to reduce atherosclerotic heart disease.
Source: Supplied
https://orcid.org/0000-0002-0682-8760
-
Exercise therapy for metabolic dysfunction-associated steatotic liver disease
Dr Shelley Keating is a Senior Lecturer in Clinical Exercise Physiology and Accredited Exercise Physiologist from the School of Human Movement and Nutrition Sciences at the University of Queensland. With a strong grounding in exercise metabolism and body composition, Dr Keating’s research centres on the utility of exercise as a therapy for obesity and related cardiometabolic conditions, notably metabolic dysfunction-associated steatotic liver disease (MASLD).
-
Next Generation Condom Contraception, Dr Simon Cook
Dr. Simon Cook, Co-Founder and Executive Director of Operations at Eudaemon Technologies, has had a diverse and impactful career journey. Beginning with a background in biotechnology from the University of Wollongong, his focus on bacterial pathogenesis during his PhD led him to study Group A Strep and the streptokinase protein.
Subsequently, Dr. Cook ventured into a unique project funded by the Bill and Melinda Gates Foundation, where he became involved in the development of a next-generation condom to address existing issues such as feel, odour, and taste.
-
Oral administration of insulin for Type 1 Diabetes
Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.
People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.
Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.
